Refine by
Patient Experience And Data Articles & Analysis
315 news found
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom ...
Summary Did you know that between 64% and 93% of dentists and dental hygienists experience work-related musculoskeletal pain?1 The solution to working pain-free might lie in better ergonomics education. Ergonomics is vital in dentistry, where professionals often work in static, awkward positions that can lead to musculoskeletal disorders and chronic pain. Proper ergonomic practices can help ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will ...
Since launching the first generation of SOPHiA DDM™ in 2015, the Platform has been at the forefront of these innovations, accelerating the practice of data driven medicine globally as a leading platform in healthcare for using data to improve patient care. ...
Planning brain surgery is a delicate process that requires precision to avoid damaging surrounding brain tissue and to prevent post-surgery complications. Synaptive Medical, a leader in medical technology, is set to enhance this process by evaluating its new software called Modus Plan, at Unity Health Toronto’s St. Michael’s Hospital, with support from OBIO’s Life Sciences ...
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer ...
ByTempus
Prophecy Market Research says it could reach US$ 508.7 billion by 2034. From data to diagnostics and imaging, drug development and discovery, early intervention and predictive analytics, remote patient monitoring and robotics, AI is revolutionizing healthcare as we know it. ...
As we look into the new year, the healthcare landscape in the UK is undergoing a number of changes. From digital transformation to evolving regulations, healthcare organisations across the UK are facing a number of challenges in 2024. We delve into five potential challenges confronting healthcare providers across the UK to help them prepare for the year ahead. ...
Caresyntax CDaaS helps partners overcome the opacity that surrounds the patient experience in the OR. While modern electronic medical records (EMR) and data warehouses provide insight to high level data like demographics, billing, and reimbursement claims, there is less discrete data output from the actual OR ...
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. The program helps AWS partners drive new business by directly connecting participating ISCs with the ...
This method uses state-of-the-art instruments that precisely measure key flow properties, including the angle of repose, bulk density, and flow rate. By obtaining accurate data on these parameters, CD Formulation aims to empower pharmaceutical companies to optimize their formulation processes. ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, in Washington. Developed in partnership with Thorasys, the Vitalograph tremoflo® C-100 oscillometer helps to detect the presence of small airway impairment, providing ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
Picosecond laser technology is a highly sought-after treatment in the field of medical aesthetics that can effectively treat all types of skin blemishes. The treatment of blemishes has long been one of the most difficult problems in the field of medical aesthetics and with the use of picosecond laser technology, there is finally a simple and effective solution to this problem. Bvlaser is a ...
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 ...
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and ...